Barclays
GYRE icon

Barclays’s Gyre Therapeutics GYRE Stock Holding History

Barclays’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-6,533
Closed -$572K – 7228
2018
Q2 		$572K Buy
+6,533
New +$1.15M ﹤0.01% 3815

Other funds holding GYRE

HH
HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Barclays's GYRE Position: Q2 2026 in Review

Barclays increased its Gyre Therapeutics (GYRE) stake by 40% in Q2 2026, buying an estimated $6.32K and bringing the position to 3,228 shares worth $21.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4569.

Barclays first reported a position in GYRE in Q2 2013 and has held it in 41 quarters since. The position peaked at $454K in Q2 2018. 60 funds tracked by Wall St. Rank hold GYRE as of Q2 2026.

  • Barclays held 3,228 shares of Gyre Therapeutics worth $21.3K as of Q2 2026.
  • Barclays bought 928 Gyre Therapeutics shares in Q2 2026, an estimated $6.32K.
  • Gyre Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4569 holding.
  • Barclays first reported a position in Gyre Therapeutics in Q2 2013 and has held it in 41 quarters since.
  • Barclays's Gyre Therapeutics position peaked at $454K in Q2 2018.
  • 60 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.